Browse FOXF1

Summary
SymbolFOXF1
Nameforkhead box F1
Aliases FREAC1; FKHL5; ACDMPV; FREAC-1; Forkhead, drosophila, homolog-like 5; forkhead-related activator 1; forkhead ......
Chromosomal Location16q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus
Domain PF00250 Forkhead domain
Function

Probable transcription activator for a number of lung-specific genes.

> Gene Ontology
 
Biological Process GO:0001570 vasculogenesis
GO:0001655 urogenital system development
GO:0001701 in utero embryonic development
GO:0001704 formation of primary germ layer
GO:0001707 mesoderm formation
GO:0001738 morphogenesis of a polarized epithelium
GO:0001756 somitogenesis
GO:0001763 morphogenesis of a branching structure
GO:0002053 positive regulation of mesenchymal cell proliferation
GO:0002263 cell activation involved in immune response
GO:0002274 myeloid leukocyte activation
GO:0002275 myeloid cell activation involved in immune response
GO:0002279 mast cell activation involved in immune response
GO:0002366 leukocyte activation involved in immune response
GO:0002443 leukocyte mediated immunity
GO:0002444 myeloid leukocyte mediated immunity
GO:0002448 mast cell mediated immunity
GO:0002683 negative regulation of immune system process
GO:0002694 regulation of leukocyte activation
GO:0002695 negative regulation of leukocyte activation
GO:0002697 regulation of immune effector process
GO:0002698 negative regulation of immune effector process
GO:0002699 positive regulation of immune effector process
GO:0002703 regulation of leukocyte mediated immunity
GO:0002704 negative regulation of leukocyte mediated immunity
GO:0002886 regulation of myeloid leukocyte mediated immunity
GO:0002887 negative regulation of myeloid leukocyte mediated immunity
GO:0003002 regionalization
GO:0003007 heart morphogenesis
GO:0003197 endocardial cushion development
GO:0003205 cardiac chamber development
GO:0003206 cardiac chamber morphogenesis
GO:0003208 cardiac ventricle morphogenesis
GO:0003214 cardiac left ventricle morphogenesis
GO:0003231 cardiac ventricle development
GO:0006887 exocytosis
GO:0007163 establishment or maintenance of cell polarity
GO:0007224 smoothened signaling pathway
GO:0007368 determination of left/right symmetry
GO:0007369 gastrulation
GO:0007389 pattern specification process
GO:0007424 open tracheal system development
GO:0007439 ectodermal digestive tract development
GO:0007440 foregut morphogenesis
GO:0007494 midgut development
GO:0007498 mesoderm development
GO:0007507 heart development
GO:0009581 detection of external stimulus
GO:0009799 specification of symmetry
GO:0009855 determination of bilateral symmetry
GO:0009952 anterior/posterior pattern specification
GO:0010463 mesenchymal cell proliferation
GO:0010464 regulation of mesenchymal cell proliferation
GO:0010810 regulation of cell-substrate adhesion
GO:0010811 positive regulation of cell-substrate adhesion
GO:0014822 detection of wounding
GO:0017157 regulation of exocytosis
GO:0030010 establishment of cell polarity
GO:0030198 extracellular matrix organization
GO:0030323 respiratory tube development
GO:0030324 lung development
GO:0030335 positive regulation of cell migration
GO:0030859 polarized epithelial cell differentiation
GO:0030879 mammary gland development
GO:0031016 pancreas development
GO:0031348 negative regulation of defense response
GO:0031589 cell-substrate adhesion
GO:0032102 negative regulation of response to external stimulus
GO:0032386 regulation of intracellular transport
GO:0032387 negative regulation of intracellular transport
GO:0032418 lysosome localization
GO:0033003 regulation of mast cell activation
GO:0033004 negative regulation of mast cell activation
GO:0033006 regulation of mast cell activation involved in immune response
GO:0033007 negative regulation of mast cell activation involved in immune response
GO:0035088 establishment or maintenance of apical/basal cell polarity
GO:0035089 establishment of apical/basal cell polarity
GO:0035239 tube morphogenesis
GO:0035282 segmentation
GO:0040017 positive regulation of locomotion
GO:0042692 muscle cell differentiation
GO:0043062 extracellular structure organization
GO:0043299 leukocyte degranulation
GO:0043300 regulation of leukocyte degranulation
GO:0043301 negative regulation of leukocyte degranulation
GO:0043303 mast cell degranulation
GO:0043304 regulation of mast cell degranulation
GO:0043305 negative regulation of mast cell degranulation
GO:0045055 regulated exocytosis
GO:0045197 establishment or maintenance of epithelial cell apical/basal polarity
GO:0045198 establishment of epithelial cell apical/basal polarity
GO:0045576 mast cell activation
GO:0045785 positive regulation of cell adhesion
GO:0045920 negative regulation of exocytosis
GO:0048286 lung alveolus development
GO:0048332 mesoderm morphogenesis
GO:0048333 mesodermal cell differentiation
GO:0048368 lateral mesoderm development
GO:0048369 lateral mesoderm morphogenesis
GO:0048370 lateral mesoderm formation
GO:0048371 lateral mesodermal cell differentiation
GO:0048514 blood vessel morphogenesis
GO:0048546 digestive tract morphogenesis
GO:0048557 embryonic digestive tract morphogenesis
GO:0048562 embryonic organ morphogenesis
GO:0048565 digestive tract development
GO:0048566 embryonic digestive tract development
GO:0048567 ectodermal digestive tract morphogenesis
GO:0048568 embryonic organ development
GO:0048611 embryonic ectodermal digestive tract development
GO:0048613 embryonic ectodermal digestive tract morphogenesis
GO:0048617 embryonic foregut morphogenesis
GO:0048732 gland development
GO:0048754 branching morphogenesis of an epithelial tube
GO:0048844 artery morphogenesis
GO:0050727 regulation of inflammatory response
GO:0050728 negative regulation of inflammatory response
GO:0050777 negative regulation of immune response
GO:0050865 regulation of cell activation
GO:0050866 negative regulation of cell activation
GO:0051048 negative regulation of secretion
GO:0051051 negative regulation of transport
GO:0051145 smooth muscle cell differentiation
GO:0051147 regulation of muscle cell differentiation
GO:0051150 regulation of smooth muscle cell differentiation
GO:0051272 positive regulation of cellular component movement
GO:0051640 organelle localization
GO:0051656 establishment of organelle localization
GO:0055123 digestive system development
GO:0060425 lung morphogenesis
GO:0060426 lung vasculature development
GO:0060438 trachea development
GO:0060441 epithelial tube branching involved in lung morphogenesis
GO:0060446 branching involved in open tracheal system development
GO:0060458 right lung development
GO:0060461 right lung morphogenesis
GO:0060462 lung lobe development
GO:0060463 lung lobe morphogenesis
GO:0060485 mesenchyme development
GO:0060541 respiratory system development
GO:0060562 epithelial tube morphogenesis
GO:0060627 regulation of vesicle-mediated transport
GO:0060644 mammary gland epithelial cell differentiation
GO:0060749 mammary gland alveolus development
GO:0060840 artery development
GO:0060841 venous blood vessel development
GO:0061030 epithelial cell differentiation involved in mammary gland alveolus development
GO:0061053 somite development
GO:0061138 morphogenesis of a branching epithelium
GO:0061162 establishment of monopolar cell polarity
GO:0061180 mammary gland epithelium development
GO:0061245 establishment or maintenance of bipolar cell polarity
GO:0061339 establishment or maintenance of monopolar cell polarity
GO:0061377 mammary gland lobule development
GO:0071407 cellular response to organic cyclic compound
GO:0072001 renal system development
GO:0072132 mesenchyme morphogenesis
GO:0072189 ureter development
GO:0090130 tissue migration
GO:0090131 mesenchyme migration
GO:0090162 establishment of epithelial cell polarity
GO:0097070 ductus arteriosus closure
GO:1903305 regulation of regulated secretory pathway
GO:1903306 negative regulation of regulated secretory pathway
GO:1903531 negative regulation of secretion by cell
GO:2000147 positive regulation of cell motility
Molecular Function GO:0001228 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding
GO:0003705 transcription factor activity, RNA polymerase II distal enhancer sequence-specific binding
Cellular Component GO:0005667 transcription factor complex
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolFOXF1
Nameforkhead box F1
Aliases FREAC1; FKHL5; ACDMPV; FREAC-1; Forkhead, drosophila, homolog-like 5; forkhead-related activator 1; forkhead ......
Chromosomal Location16q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between FOXF1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolFOXF1
Nameforkhead box F1
Aliases FREAC1; FKHL5; ACDMPV; FREAC-1; Forkhead, drosophila, homolog-like 5; forkhead-related activator 1; forkhead ......
Chromosomal Location16q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of FOXF1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolFOXF1
Nameforkhead box F1
Aliases FREAC1; FKHL5; ACDMPV; FREAC-1; Forkhead, drosophila, homolog-like 5; forkhead-related activator 1; forkhead ......
Chromosomal Location16q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of FOXF1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.8590.0464
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.0060.148
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.7670.211
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1410.873
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.450.824
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.8820.711
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.8580.226
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.4720.657
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11121.1080.299
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.1960.642
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.6030.293
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.4750.0354
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of FOXF1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.703.70.27
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolFOXF1
Nameforkhead box F1
Aliases FREAC1; FKHL5; ACDMPV; FREAC-1; Forkhead, drosophila, homolog-like 5; forkhead-related activator 1; forkhead ......
Chromosomal Location16q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FOXF1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolFOXF1
Nameforkhead box F1
Aliases FREAC1; FKHL5; ACDMPV; FREAC-1; Forkhead, drosophila, homolog-like 5; forkhead-related activator 1; forkhead ......
Chromosomal Location16q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FOXF1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FOXF1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolFOXF1
Nameforkhead box F1
Aliases FREAC1; FKHL5; ACDMPV; FREAC-1; Forkhead, drosophila, homolog-like 5; forkhead-related activator 1; forkhead ......
Chromosomal Location16q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FOXF1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolFOXF1
Nameforkhead box F1
Aliases FREAC1; FKHL5; ACDMPV; FREAC-1; Forkhead, drosophila, homolog-like 5; forkhead-related activator 1; forkhead ......
Chromosomal Location16q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of FOXF1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolFOXF1
Nameforkhead box F1
Aliases FREAC1; FKHL5; ACDMPV; FREAC-1; Forkhead, drosophila, homolog-like 5; forkhead-related activator 1; forkhead ......
Chromosomal Location16q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between FOXF1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolFOXF1
Nameforkhead box F1
Aliases FREAC1; FKHL5; ACDMPV; FREAC-1; Forkhead, drosophila, homolog-like 5; forkhead-related activator 1; forkhead ......
Chromosomal Location16q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting FOXF1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.